skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

Refine Results

Clear All


Show More


Show More

Show More


Show More

Show More

44 Total results for product and free and sample content found

Datamonitor Healthcare: 医療用医薬品の市場調査レポート

Alnylam and partner Sanofi deliver on their RNAi promise with groundbreaking results in rare polyneuropathy condition

08 Oct 2017

Alnylam’s high stakes investment in RNAi therapeutics delivers a major short-term win for stakeholders, but long-term commercial success is still in question.

Topic biopharmaceutical

Datamonitor Healthcare: 医療用医薬品の市場調査レポート

Allergan uses Native American tribe’s sovereign immunity to delay generic entry

08 Oct 2017

Allergan’s deal with the Saint Regis Mohawk Tribe will shore up revenue from its top-selling dry eye drug Restasis in the short term.

Topic Company analysis

Datamonitor Healthcare: 医療用医薬品の市場調査レポート

Gilead expands into CAR-T therapy with $11.9bn purchase of Kite Pharmaceuticals

By Oliver Spray 08 Oct 2017

Pharmavitae Analytics expects Gilead’s purchase of Kite to generate long-term growth for Gilead.

Topic company-analysis

Datamonitor Healthcare: 医療用医薬品の市場調査レポート

Xtandi will have first-mover advantage in non-metastatic prostate cancer setting

By Edward Thomason 08 Oct 2017

Positive results from the Phase III PROSPER trial ( identifier

Topic Cancer

Medtech Insight: 世界の医療機器・医療技術の最新情報

UK Viewpoint: Tech & Innovation In Focus In NHS Chief's 'Forward View'

By Ashley Yeo 04 Apr 2017

Filtering out the background noise, NHS England's chief executive tends to give a straightforward account of the state and the needs of the national health care provider. He did just that in a mid-term update of the NHS Five Year Forward View on March 31.

Datamonitor Healthcare: 医療用医薬品の市場調査レポート

Ocrevus FDA approval marks watershed moment for MS market

03 Apr 2017

Roche’s exciting new multiple sclerosis (MS) drug Ocrevus (ocrelizumab) was approved by the US Food and Drug Administration (FDA) on 29 March 2017 (Roche, 2017). The drug is indicated for relapsing-remitting MS (RRMS) on the strength of the two OPERA studies, which showed clear superiority over the current standard of care, Rebif (interferon beta-1a; Merck KGaA/Pfizer).

Topic FDA Multiple Sclerosis

Datamonitor Healthcare: 医療用医薬品の市場調査レポート

Disappointing Translarna failure is an isolated event for CF pipeline

30 Mar 2017

PTC Therapeutics announced the failure of its ACT CF trial of Translarna (ataluren) in nonsense mutation cystic fibrosis (nmCF) patients, bringing a halt to any further planned developmental activities in the indication. Although there was a slight treatment effect, Translarna failed to significantly improve pulmonary measures compared to placebo.

Topic comment-wire

Datamonitor Healthcare: 医療用医薬品の市場調査レポート

After several setbacks, Xadago has received a less than ideal FDA approval in Parkinson’s disease

By Stephanie Yip 28 Mar 2017

On 21 March 2017, Newron Pharmaceuticals and its partners Zambon and US WorldMeds announced the approval of Xadago (safinamide) for the treatment of Parkinson’s disease (PD) as an add-on therapy to levodopa/carbidopa for patients experiencing “off” periods (BusinessWire, 2017; FDA press release, 2017). This approval was long-awaited by Newron and its US partner, US WorldMeds, as it followed numerous earlier US regulatory setbacks. Newron and its partner are now looking to successfully launch Xadago, but the US approved label fell short of ideal as it did not extend to early-stage PD patients receiving dopamine agonists  

Topic diseases parkinsons-disease

Datamonitor Healthcare: 医療用医薬品の市場調査レポート

ACC 2017 – FOURIER CVOT data spur physician demand for Repatha, but reimbursement will remain a major barrier

27 Mar 2017

Results from the Phase III FOURIER trial in high-risk patients with atherosclerotic cardiovascular disease (ASCVD) find that Repatha treatment results in significant reductions in rates of stroke and myocardial infarction. These positive results have excited physicians, although it is likely that reimbursement will remain strict since payers did not view the results as positively as physicians.

Topic diseases





電話:+81 (0)3 6273 4260